In Brief: Generic ranitidine
Generic ranitidine: Appeals court will hold emergency hearing July 22 to reconsider July 9 injunction preventing FDA from approving Novopharm's ANDA in time for a July 10 launch ("The Pink Sheet" July 14, T&G-1). Should the stay remain in place, the earliest FDA could theoretically approve a ranitidine ANDA would be Aug. 29 -- the date it determined Genpharm's generic exclusivity period will expire -- unless Genpharm resolves the patent suit brought by Glaxo or licenses its exclusivity to another firm with tentative approval...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth